BLFS BioLife Solutions, Inc. featured news, full reports, and detailed charts
BioLife Solutions, Inc. (BLFS/BLFS.OB) Wrap Up:
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of proprietary hypothermic storage and cryopreservation solutions for cells, tissues, and organs. Its proprietary HypoThermosol and CryoStor solutions are marketed to companies, laboratories, and academic institutions involved in research and commercial clinical applications. The company’s line of serum-free and protein-free preservation solutions are formulated to reduce preservation-induced, delayed-onset cell damage, and death. Its HypoThermosol series of products include HypoThermosol FRS to decrease the free radical accumulation in cells undergoing hypothermic preservation; and HypoThermosol Purge, an acellul...BioLife Solutions, Inc. (BLFS:OTC Bulletin Board Market)
Snapshot of BioLife Solutions, Inc. (BLFS)
|
OPEN
$0.09
|
PREVIOUS CLOSE
$0.11
|
|
|
DAY HIGH
$0.09
|
DAY LOW
$0.09
|
|
|
52 WEEK HIGH
09/15/09 - $0.25
|
52 WEEK LOW
12/10/08 - $0.02
|
|
|
MARKET CAP
6.3M
|
AVERAGE VOLUME 3 mo
13.2K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
69.6M
|
|
|
BLFS Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
BLFS Top Compensated Officers
Executives, Board Directors
Key developments for BioLife Solutions, Inc. (BLFS)
BioLife Solutions Inc. announced that Sigma-Aldrich Co. will distribute the company's proprietary HypoThermosol and CryoStor biopreservation media products under the terms of a non-exclusive distribution agreement.
BioLife Solutions Inc. announced the launch of its BloodStor biopreservation media product platform. The product family includes BloodStor 55-5 for cryopreservation of umbilical cord blood stem cells, as well as other variants for peripheral blood derived stem cells. BloodStor 55-5, packaged in standard, single-use sterile vials of various fill volumes, is formulated with 55% USP grade DMSO and 5% USP grade dextran-40 in water for injection quality (WFI) water and supports a common cord blood processing protocol.
BioLife Solutions Inc. announced that it has entered into a non-exclusive distribution agreement with STEMCELL Technologies Inc.
BLFS Competitors
| Company | Last | Change |
| Life Technologies Corp | $49.48 USD | -0.31 |
| Sigma Aldrich Corp | $53.94 USD | +0.06 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | BLFS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 5.5x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.4x |
|
|
BLFS |
||
BLFS transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||